These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 35693078)

  • 21. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
    van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
    JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study.
    Su YY; Chiu YF; Li CP; Yang SH; Lin J; Lin SJ; Chang PY; Chiang NJ; Shan YS; Ch'ang HJ; Chen LT
    Br J Cancer; 2022 Apr; 126(7):1018-1026. PubMed ID: 34921230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimated Projection of US Cancer Incidence and Death to 2040.
    Rahib L; Wehner MR; Matrisian LM; Nead KT
    JAMA Netw Open; 2021 Apr; 4(4):e214708. PubMed ID: 33825840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial.
    Cascinu S; Berardi R; Bianco R; Bilancia D; Zaniboni A; Ferrari D; Mosconi S; Spallanzani A; Cavanna L; Leo S; Negri F; Beretta GD; Sobrero A; Banzi M; Morabito A; Bittoni A; Marciano R; Ferrara D; Noventa S; Piccirillo MC; Labianca R; Mosconi C; Casadei Gardini A; Gallo C; Perrone F
    Eur J Cancer; 2021 May; 148():422-429. PubMed ID: 33812334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
    Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
    CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pancreatic cancer.
    Mizrahi JD; Surana R; Valle JW; Shroff RT
    Lancet; 2020 Jun; 395(10242):2008-2020. PubMed ID: 32593337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis.
    Okusaka T; Nakamura M; Yoshida M; Kitano M; Uesaka K; Ito Y; Furuse J; Hanada K; Okazaki K;
    Pancreas; 2020 Mar; 49(3):326-335. PubMed ID: 32132516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.
    Chiang NJ; Tsai KK; Hsiao CF; Yang SH; Hsiao HH; Shen WC; Hsu C; Lin YL; Chen JS; Shan YS; Chen LT
    Eur J Cancer; 2020 Jan; 124():123-130. PubMed ID: 31765987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review.
    Napolitano F; Formisano L; Giardino A; Girelli R; Servetto A; Santaniello A; Foschini F; Marciano R; Mozzillo E; Carratù AC; Cascetta P; De Placido P; De Placido S; Bianco R
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31337045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The incidence and survival of pancreatic cancer by histology, including rare subtypes: a nation-wide cancer registry-based study from Taiwan.
    Chang JS; Chen LT; Shan YS; Chu PY; Tsai CR; Tsai HJ
    Cancer Med; 2018 Nov; 7(11):5775-5788. PubMed ID: 30264519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection.
    Gemenetzis G; Groot VP; Blair AB; Laheru DA; Zheng L; Narang AK; Fishman EK; Hruban RH; Yu J; Burkhart RA; Cameron JL; Weiss MJ; Wolfgang CL; He J
    Ann Surg; 2019 Aug; 270(2):340-347. PubMed ID: 29596120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pancreatic Cancer and FOLFIRINOX: Should We Resect All Responders?
    Neoptolemos JP; Halloran CM; Ghaneh P; Kleeff J
    Ann Surg; 2018 Feb; 267(2):e35-e36. PubMed ID: 29300711
    [No Abstract]   [Full Text] [Related]  

  • 35. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.
    Isaji S; Mizuno S; Windsor JA; Bassi C; Fernández-Del Castillo C; Hackert T; Hayasaki A; Katz MHG; Kim SW; Kishiwada M; Kitagawa H; Michalski CW; Wolfgang CL
    Pancreatology; 2018 Jan; 18(1):2-11. PubMed ID: 29191513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma.
    Reni M; Zanon S; Balzano G; Nobile S; Pircher CC; Chiaravalli M; Passoni P; Arcidiacono PG; Nicoletti R; Crippa S; Slim N; Doglioni C; Falconi M; Gianni L
    Ann Oncol; 2017 Nov; 28(11):2786-2792. PubMed ID: 28945895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary.
    Balaban EP; Mangu PB; Yee NS
    J Oncol Pract; 2017 Apr; 13(4):265-269. PubMed ID: 28399382
    [No Abstract]   [Full Text] [Related]  

  • 38. Neoadjuvant Therapy in Resectable Pancreatic Cancer: Immortal Time Bias and Its Correction.
    Lai TY; Hu YW
    J Clin Oncol; 2017 May; 35(14):1623. PubMed ID: 28135147
    [No Abstract]   [Full Text] [Related]  

  • 39. Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients.
    Hackert T; Sachsenmaier M; Hinz U; Schneider L; Michalski CW; Springfeld C; Strobel O; Jäger D; Ulrich A; Büchler MW
    Ann Surg; 2016 Sep; 264(3):457-63. PubMed ID: 27355262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
    Suker M; Beumer BR; Sadot E; Marthey L; Faris JE; Mellon EA; El-Rayes BF; Wang-Gillam A; Lacy J; Hosein PJ; Moorcraft SY; Conroy T; Hohla F; Allen P; Taieb J; Hong TS; Shridhar R; Chau I; van Eijck CH; Koerkamp BG
    Lancet Oncol; 2016 Jun; 17(6):801-810. PubMed ID: 27160474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.